Intuitive Surgical’s 2026 Conundrum: Record Earnings Meet a 52-Week Low
Intuitive Surgical reported Q2 adjusted EPS of $2.80 vs $2.48 expected and revenue of $2.89B vs $2.83B, but its stock fell to a fresh 52-week low around €289.05. The company cited slower US procedure growth and lowered full-year guidance range to 13.5% to 15.5%. Competition includes FDA-cleared J&J OTTAVA.
How this was made
The 30-second read
Why it matters
Traders should focus on the revised full-year procedure growth guidance and the stated drivers (ACA subsidy expiration, semiconductor and freight cost increases), since these directly affect forward estimates and valuation support.
Market read
A same-day earnings beat fails to prevent a 52-week low because guidance and procedure-growth deceleration dominate the narrative, with added competitive risk from new FDA-cleared entrants.
What to watch
The article cites a competitor’s FDA clearance and institutional buying, which could indicate the market is over-weighting near-term procedure growth deceleration versus longer-term installed-base economics.
Background
ISRG’s da Vinci installed base is expanding and the quarter showed strong EPS and revenue versus consensus, but the market is focused on slowing procedure growth and margin headwinds.
Ticker impact
Intuitive Surgical reported Q2 EPS of $2.80 and revenue of $2.89B, but guided procedure growth down and shares hit a 52-week low.
Near-term pressure likely persists until procedure growth re-accelerates or margins stabilize; oversold conditions may support a technical bounce.
The article’s newest decision-relevant facts are the procedure growth deceleration, the full-year guidance range reduction, and margin headwinds from semiconductors and freight, all of which directly affect ISRG’s forward outlook despite the EPS/revenue beat.
Market effects
Medtech and surgical robotics investors may reprice on procedure-growth sensitivity and margin pressure, even when top-line and EPS beat.
US procedure growth deceleration and ACA subsidy expiration are US-specific read-throughs for demand timing.
Competitive dynamics in soft-tissue robotics could pressure global expectations for procedure growth and installed-base monetization.
Counterpoint
The installed base is still growing and recurring revenue is ~85% of sales, so the guidance cut may be a temporary demand timing issue rather than a durable demand collapse.
Key entities
- companyIntuitive Surgical
Robotic surgery company reporting Q2 beat while cutting full-year procedure growth guidance due to ACA subsidy expiration and cost pressures.
- companyJohnson & Johnson
Received FDA De Novo clearance for its OTTAVA robotic surgical system, introducing competitive uncertainty for soft-tissue robotics.
- companyMomentis Surgical
Received FDA clearance for multiport configuration of its Anovo system; co-founder Frederic Moll is on its board.
%252FIntuitive%252520Surgical%252520Inc%252520location%252520sign-by%252520Sundry%252520Photography%252520via%252520iStock.jpg&w=3840&q=75)